Recommendations Summary
PDM: Weight Loss and Prevention of Type 2 Diabetes 2014
Click here to see the explanation of recommendation ratings (Strong, Fair, Weak, Consensus, Insufficient Evidence) and labels (Imperative or Conditional). To see more detail on the evidence from which the following recommendations were drawn, use the hyperlinks in the Supporting Evidence Section below.
-
Recommendation(s)
PDM: Weight Loss and Prevention of Type 2 Diabetes
- For individuals who are at high risk for type 2 diabetes who are overweight or obese, the registered dietitian nutritionist (RDN) should prescribe a weight-reducing diet and support weight loss using evidence-based nutrition practice guidelines
- In adults with metabolic syndrome, research regarding a weight loss achieved via lifestyle modification over at least a three-month period ranging from 1.1kg to 13kg reported significant improvements:
- Decreased A1C by 0.12% to 0.3%
- Decreased triglycerides by 20mg to 132mg per dL (0.23mmol to 1.5mmol per L)
- Decreased waist circumference by 1.5cm to 11cm
- Decreased systolic blood pressure by 4.9mm Hg to 10mm Hg.
- In individuals with prediabetes, research regarding a weight loss achieved via lifestyle modification over at least a three-month period ranging from 2.6kg to 7.1kg reported significant improvements:
- Decreased fasting glucose levels by 2.2mg to 9.2mg per dL (0.12mmol to 0.5mmol per L)
- Decreased triglyceride levels by 30.9mg per dL (0.35mmol per L)
- Decreased waist circumference by 1.3cm to 5.9cm
- Decreased systolic blood pressure 3.5mm Hg to 6mm Hg and diastolic blood pressure by 5mm Hg.
- In individuals with prediabetes, research regarding a weight loss achieved via bariatric surgery of up to 47kg or 41% of excess BMI over a period of three to five years reported significant improvements:
- Decreased fasting glucose levels by 16.2mg to 20.9mg per dL (0.9mmol to 1.16mmol per L)
- Decreased two-hour post-prandial glucose levels by 16mg per dL (0.9mmol per L)
- Decreased A1C by 0.5%.
- Decreased triglyceride levels by 70.6mg per dL (0.8mmol per L)
- Increased HDL cholesterol levels by 1.9mg per dL (0.05mmol per L)
- Decreased systolic blood pressure by 6mm Hg.
Rating: Strong
Conditional-
Risks/Harms of Implementing This Recommendation
- Reduction of caloric intake may result in nutritional inadequacies; therefore, special attention should be paid to maintaining adequate intake of vitamins and minerals
- Adverse risks may be associated with pharmacotherapy and bariatric surgery.
-
Conditions of Application
- This recommendation applies to individuals who are at high risk for type 2 diabetes who are overweight or obese
- For evidence-based weight loss methods, please refer to the following projects:
- Adult Weight Management Evidence-Based Nutrition Practice Guideline: http://andevidencelibrary.com/topic.cfm?cat=2798
- Pediatric Weight Management Evidence-Based Nutrition Practice Guideline: http://andevidencelibrary.com/topic.cfm?cat=2721:
- Vegetarian Nutrition Evidence-Based Nutrition Practice Guideline: http://andevidencelibrary.com/topic.cfm?cat=4021.
-
Potential Costs Associated with Application
The costs of medical nutrition therapy (MNT).
-
Recommendation Narrative
A total of 28 studies (30 publications) were included in the evidence analysis for this recommendation:
- Twelve positive-quality randomized controlled trials (RCT) (Lee et al, 2009; Al-Sarraj et al, 2010; Klemsdal et al, 2010; Straznicky et al, 2010; Busnello et al, 2011; Christian et al, 2011; Gagnon et al, 2011; Lu et al, 2011; Munakata et al, 2011; Sakane et al, 2011; Straznicky et al, 2011; Straznicky et al, 2012)
- Nine neutral-quality randomized controlled trials (RCT) (Chan et al, 2008; Burtscher et al, 2009; Ng et al, 2009; Yassine et al, 2009; Mujica et al, 2010; Oh et al, 2010; Parikh et al, 2010; Katula et al, 2011; Seligman et al, 2011)
- Two positive-quality cohort studies (Caiazzo et al, 2010; de la Cruz-Munoz et al, 2011)
- Two neutral-quality cohort studies (Allen et al, 2008; Bihan et al, 2009)
- One neutral-quality case-control study (Aizawa et al, 2009)
- Three neutral-quality non-randomized controlled trials (Cicero et al, 2009; Kim et al, 2009; Evangelou et al, 2010)
- One positive-quality systematic review (Orozco et al, 2008).
In Adults with Metabolic Syndrome
- Glycemic-related outcomes (FBG, random BG, two-hour post-prandial BG, A1C):
- Most studies reported no significant impact of weight loss on fasting glucose levels in adults with metabolic syndrome. However, of two intervention studies reporting A1C values, both demonstrated that weight loss significantly reduced A1C by 0.12% to 0.3%
- Additional longer-term intervention studies are needed to ascertain an effect of weight loss on glycemic-related outcomes in adults with metabolic syndrome with or without meeting the metabolic syndrome criteria for impaired glucose tolerance and impaired fasting glucose
- Evidence is based on the following: Chan et al, 2008; Aizawa et al, 2009; Bihan et al, 2009; Cicero et al, 2009; Kim et al, 2009; Lee et al, 2009; Ng et al, 2009; Yassine et al, 2009; Evangelou et al, 2010; Mujica et al, 2010; Oh et al, 2010; Straznicky et al, 2010; Busnello et al, 2011; Christian et al, 2011; Munakata et al, 2011; Straznicky et al, 2011; Straznicky et al, 2012.
- Lipid outcomes (TG, HDL):
- The majority of research reported that a weight loss ranging from 1.1kg to 13kg significantly reduced triglyceride levels by 20mg to 132mg per (0.23mmol to 1.5mmol per L) in adults with metabolic syndrome
- Most studies reported no significant impact of weight loss on HDL cholesterol levels in adults with metabolic syndrome
- Evidence is based on the following: Chan et al, 2008; Aizawa et al, 2009; Bihan et al, 2009; Cicero et al, 2009; Kim et al, 2009; Lee et al, 2009; Ng et al, 2009; Yassine et al, 2009; Al Sarraj et al, 2010; Evangelou et al, 2010; Mujica et al, 2010; Oh et al, 2010; Straznicky et al, 2010; Busnello et al, 2011; Christian et al, 2011; Munakata et al, 2011; Straznicky et al, 2011; Straznicky et al, 2012.
- Anthropometric outcomes (WC, WHR):
- Research reports that a weight loss ranging from 1.1kg to 13kg significantly reduced waist circumference by 1.5cm to 11cm in adults with metabolic syndrome
- However, most studies reported no significant impact of weight loss on waist-to-hip ratio in adults with metabolic syndrome
- Evidence is based on the following: Chan et al, 2008; Aizawa et al, 2009; Bihan et al, 2009; Kim et al, 2009; Lee et al, 2009; Ng et al, 2009; Yassine et al, 2009; Evangelou et al, 2010; Klemsdal et al, 2010; Mujica et al, 2010; Oh et al, 2010; Straznicky et al, 2010; Busnello et al, 2011; Christian et al, 2011; Munakata et al, 2011; Seligman et al, 2011; Straznicky et al, 2011; Straznicky et al, 2012.
- Blood pressure outcomes:
- Most studies reported that a weight loss ranging from 1.1kg to 8.4kg significantly reduced systolic blood pressure by 4.9mm Hg to 10mm Hg in adults with metabolic syndrome
- However, the research regarding weight loss reports mixed results on diastolic blood pressure in adults with metabolic syndrome
- Additional longer-term intervention studies are needed to ascertain an effect of weight loss on blood pressure in adults with metabolic syndrome with or without meeting the metabolic syndrome criteria for blood pressure
- Evidence is based on the following: Chan et al, 2008; Aizawa et al, 2009; Bihan et al, 2009; Kim et al, 2009; Yassine et al, 2009; Evangelou et al, 2010; Mujica et al, 2010; Oh et al, 2010; Straznicky et al, 2010; Christian et al, 2011; Munakata et al, 2011; Straznicky et al, 2011; Straznicky et al, 2012.
- Renal outcomes:
- Two intervention studies regarding the impact of weight loss on renal outcomes reported inconclusive results
- Additional longer-term intervention studies are needed to ascertain an effect of weight loss on renal outcomes in adults with metabolic syndrome with or without meeting the metabolic syndrome criteria for urinary albumin excretion rate or albumin:creatinine ratio
- Evidence is based on the following: Seligman et al, 2011; Straznicky et al, 2011.
In Individuals with Prediabetes
- Glycemic-related outcomes (FBG, random BG, two-hour post-prandial BG, A1C):
- The majority of lifestyle modification intervention studies reported that weight loss significantly reduces fasting blood glucose in individuals with prediabetes, while most studies report no significant impact of weight loss on two-hour post-prandial blood glucose or A1C
- Of those studies reporting a weight loss ranging from 2.6kg to 7.1kg, there was a significant reduction in fasting blood glucose levels by 2.2mg to 9.2mg per dL (0.12mmol to 0.5mmol per L)
- In bariatric surgery intervention studies, a weight loss of up to 47kg or 41% of excess BMI over a period of three to five years significantly reduced fasting glucose levels by 16.2mg to 20.9mg per dL (0.9mmol to 1.16mmol per L), two-hour glucose levels by 16mg per dL (0.9mmol per L) and A1C by 0.5%
- Additional lifestyle modification intervention studies are needed to ascertain the effects of weight loss on two-hour post-prandial blood glucose and A1C in individuals with prediabetes
- Evidence is based on the following: Allen et al, 2008; Orozco et al, 2008; Burtscher et al, 2009; Caiazzo et al, 2010; Parikh et al, 2010; de la Cruz-Munoz et al, 2011; Gagnon et al, 2011; Katula et al, 2011; Lu et al, 2011, Sakane et al, 2011.
- Lipid outcomes (TG, HDL):
- Most lifestyle modification intervention studies reported that weight loss improves triglyceride levels, but does not have a significant impact on HDL cholesterol levels, in individuals with prediabetes
- In the study reporting a weight loss of 2.7kg, there was a significant reduction in triglyceride levels by 30.9mg per dL (0.35mmol per L)
- In one bariatric surgery intervention study, a weight loss of up to 41% of excess BMI significantly decreased triglyceride levels by 70.6mg per dL (0.8mmol per L) and increased HDL cholesterol levels by 1.9mg per dL (0.05mmol per L)
- Additional lifestyle modification intervention studies are needed to ascertain the effects of weight loss on lipid outcomes in individuals with prediabetes
- Evidence is based on the following: Allen et al, 2008; Orozco et al, 2008; Burtscher et al, 2009; Caiazzo et al, 2010; Gagnon et al, 2011; Lu et al, 2011, Sakane et al, 2011.
- Anthropometric outcomes (WC, WHR):
- The majority of lifestyle modification intervention studies reported that weight loss significantly reduces waist circumference, but does not have a significant impact on waist-to-hip ratio, in individuals with prediabetes
- Of those studies reporting a weight loss ranging from 2.7kg to 7.1kg, there was a significant reduction in waist circumference by 1.3cm to 5.9cm
- Evidence is based on the following: Allen et al, 2008; Orozco et al, 2008; Parikh et al, 2010; Gagnon et al, 2011; Katula et al, 2011; Lu et al, 2011, Sakane et al, 2011.
- Blood pressure outcomes:
- Most lifestyle modification intervention studies reported that weight loss significantly reduces systolic and diastolic blood pressure in individuals with prediabetes
- Of those studies reporting a weight loss ranging from 2.7kg to 4.9kg, there was a significant reduction in systolic blood pressure of 3.5mm Hg to 6mm Hg and in diastolic blood pressure of 5mm Hg
- In one bariatric surgery intervention study, a weight loss of up to 41% of excess BMI significantly reduced systolic blood pressure by 6mm Hg
- Evidence is based on the following: Allen et al, 2008; Orozco et al, 2008; Burtscher et al, 2009; Caiazzo et al, 2010; Parikh et al, 2010; Gagnon et al, 2011; Lu et al, 2011, Sakane et al, 2011.
-
Recommendation Strength Rationale
For Adults with Metabolic Syndrome
- Grade I evidence is available for the conclusion statements regarding the impact of weight loss for at least a three-month period on the following outcomes:
- Lipid (TG, HDL)
- Anthropometric measures (WC, WHR).
- Grade II evidence is available for the conclusion statements regarding the impact of weight loss for at least a three-month period on the following outcomes:
- Glycemic-related outcomes (such as fasting blood glucose, random blood glucose, two-hour post-prandial blood glucose, A1C)
- Blood pressure.
- Grade III evidence is available for the conclusion statements regarding the impact of weight loss for at least a three-month period on the following outcomes: Renal outcomes.
For Individuals with Prediabetes
- Grade I evidence is available for the conclusion statements regarding the impact of weight loss for at least a three-month period on the following outcomes:
- Glycemic-related outcomes (such as fasting blood glucose, random blood glucose, two-hour post-prandial blood glucose, A1C)
- Anthropometric measures (WC, WHR)
- Blood pressure.
- Grade II evidence is available for the conclusion statements regarding the impact of weight loss for at least a three-month period on the following outcomes: Lipid (TG, HDL).
- Grade I evidence is available for the conclusion statements regarding the impact of weight loss for at least a three-month period on the following outcomes:
-
Minority Opinions
Consensus reached.
-
Supporting Evidence
The recommendations were created from the evidence analysis on the following questions. To see detail of the evidence analysis, click the blue hyperlinks below (recommendations rated consensus will not have supporting evidence linked).
In adults with metabolic syndrome, what is the impact of weight loss (over at least a three-month period) on glycemic-related outcomes (such as fasting blood glucose, random blood glucose, two-hour post-prandial blood glucose, A1C)?
In adults with metabolic syndrome, what is the impact of weight loss (over at least a three-month period) on lipid outcomes (TG, HDL)?
In adults with metabolic syndrome, what is the impact of weight loss (over at least a three-month period) on anthropometric outcomes (WC, WHR)?
In adults with metabolic syndrome, what is the impact of weight loss (over at least a three-month period) on blood pressure?
In adults with metabolic syndrome, what is the impact of weight loss (over at least a three-month period) on renal outcomes?
In individuals with prediabetes, what is the impact of weight loss (over at least a three-month period) on glycemic-related outcomes (such as fasting blood glucose, random blood glucose, two-hour post-prandial blood glucose, A1C)?
In individuals with prediabetes, what is the impact of weight loss (over at least a three-month period) on lipid outcomes (TG, HDL)?
In individuals with prediabetes, what is the impact of weight loss (over at least a three-month period) on anthropometric outcomes (WC, WHR)?
In individuals with prediabetes, what is the impact of weight loss (over at least a three-month period) on blood pressure?-
References
Aizawa K, Shoemaker JK, Overend TJ, Petrella RJ. Effects of lifestyle modification on central artery stiffness in metabolic syndrome subjects with pre-hypertension and/or pre-diabetes. Diabetes Res Clin Pract. 2009; 83: 249-256.
Bihan H, Takbou K, Cohen R, Michault A, Boitou F, Reach G, Le Clesiau H. Impact of short-duration lifestyle intervention in collaboration with general practitioners in patients with the metabolic syndrome. Diabetes & Metabolism. 2009; 35: 185-191.
Busnello FM, Bodanese LC, Pellanda LC, Santos ZE. Nutritional intervention and the impact on adherence to treatment in patients with metabolic syndrome. Arq Bras Cardiol. 2011; 97(3): 217-224.
Chan DC, Watts GF, Ng TWK, Yamashita S, Barrett, PHR. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. Eur J Clin Invest. 2008; 38 (10): 743-751.
Christian JG, Byers TE, Christian KK, Goldstein MG, Bock BC, Prioreschi B, Bessesen DH. A computer support program that helps clinicians provide patients with metabolic syndrome tailored counseling to promote weight loss. J Am Diet Assoc. 2011; 111(1): 75-83.
Cicero AF, Derosa G, Bove M, Di Gregori V, Gaddi AV, Borghi C. Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. Eur J Cardiovasc Prev Rehabil. 2009; 16(6): 698-704.
Evangelou P, Tzotzas T, Christou G, Elisaf MS, Kiortsis DN. Does the presence of metabolic syndrome influence weight loss in obese and overweight women? Metab Syndr Relat Disord. 2010; 8(2): 173-178.
Kim MK, Tanaka K, Kim MJ, Matsuo T, Ajisaka R. Exercise training-induced changes in heart rate recovery in obese men with metabolic syndrome. Metab Syndr Relat Disord. 2009 Oct; 7 (5): 469-476.
Lee K, Lee J, Bae WK, Choi JK, Kim HJ, Cho B. Efficacy of low-calorie, partial meal replacement diet plans on weight and abdominal fat in obese subjects with metabolic syndrome: A double-blind, randomized controlled trial of two diet plans - one high in protein and one nutritionally balanced. Int J Clin Pract. 2009; 63(2): 195-201.
Mujica V, Urzua A, Leiva E, Diaz N, Moore-Carrasco R, Vasquez M, Rojas E, Icaza G, Toro C, Orrego R, Palomo I. Intervention with education and exercise reverses the metabolic syndrome in adults. J Am Soc Hypertens. 2010; 4(3): 148-153.
Munakata M, Honma H, Akasi M, Araki T, Kawamura T, Kubota M, Yokokawa T, Numata Y, Toyonaga T, J-STOP-MetS Study Group. Repeated counselling improves the antidiabetic effects of limited individualized lifestyle guidance in metabolic syndrome: J-STOP-METS final results. Hypertens Res. 2011; 34 (5): 612-616.
Ng TW, Chan DC, Barrett PH, Watts GF. Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome. Clin Sci (Lond). 2009; 118(1): 79-85.
Oh EG, Bang SY, Hyun SS, Kim SH, Chu SH, Jeon JY, Im JA, Lee MK, Lee JE. Effects of a six-month lifestyle modification intervention on the cardiometabolic risk factors and health-related qualities of life in women with metabolic syndrome. Metabolism. 2010; 59(7): 1,035-1,043.
Straznicky NE, Grima MT, Lambert EA, Eikelis N, Dawood T, Lambert GW, Nestel PJ, Masuo K, Sari CI, Chopra R, Mariani JA, Schlaich MP. Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J Hypertens. 2011; 29(3): 553-564.
Straznicky NE, Lambert EA, Nestel PJ, McGrane MT, Dawood T, Schlaich MP, Masuo K, Eikelis N, de Courten B, Mariani JA, Esler MD, Socratous F, Chopra R, Sari CI, Paul E, Lambert GW. Sympathetic neural adaptation to hypocaloric diet with or without exercise training in obese metabolic syndrome subjects. Diabetes. 2010; 59(1): 71-79.
Straznicky NE, Lambert EA, Grima MT, Eikelis N, Nestel PJ, Dawood T, Schlaich MP, Masuo K, Chopra R, Sari CI, Dixon JB, Tilbrook AJ, Lambert GW. The effect of dietary weight loss with or without exercise training on liver enzymes in obese metabolic syndrome subjects. Diabetes Obes Metab. 2012; 14(2): 139-148.
Yassine HN, Marchetti CM, Krishnan RK, Vrobel TR, Gonzalez F, Kirwan JP. Effects on exercise and caloric restriction on insulin resistance and cardiometabolic risk factors in older obese adults: A randomized clinical trial. J Gerontol A Biol Sci Med Sci. 2009; 64: 90-95.
Al-Sarraj T, Saadi H, Volek JS, Fernandez ML. Metabolic syndrome prevalence, dietary intake, and cardiovascular risk profile among overweight and obese adults 18-50 years old from the United Arab Emirates. Metab Syndr Relat Disord. 2010; 8 (1): 39-46.
Klemsdal TO, Holme I, Nerland H, Pedersen TR, Tonstad S. Effects of a low glycemic load diet vs. a low-fat diet in subjects with and without the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2010; 20 (3): 195-201.
Seligman BG, Polanczyk CA, Santos AS, Foppa M, Junges M, Bonzanini L, Nicolaidis G, Carney S, Lopes AL, Sehl P, Duncan BB, Clausell N. Intensive practical lifestyle intervention improves endothelial function in metabolic syndrome independent of weight loss: A randomized controlled trial. Metabolism. 2011; 60(12): 1,736-1,740.
Allen P, Thompson JL, Herman CJ, Qualls C, Helitzer DL, Whyte AN, Wolfe VK. Impact of periodic follow-up testing among urban American Indian women with impaired fasting glucose. Prev Chronic Dis. 2008; 5(3): A76.
Burtscher M, Gatterer H, Kunczicky H, Brandstatter E, Ulmer H. Supervised exercise in patients with impaired fasting glucose: Impact on exercise capacity. Clin J. Sport Med. 2009; 19 (5): 394-398.
Caiazzo R, Arnalsteen L, Pigeyre M, Dezfoulian G, Verkindt G, Kirkby-Bott J, Mathurin P, Fontaine P, Romon M, Pattou F. Long-term metabolic outcome and quality of life after laparoscopic adjustable gastric banding in obese patients with type 2 diabetes mellitus or impaired fasting glucose. Br J Surg. 2010; 97(6): 884-891.
de la Cruz-Munoz N, Messiah SE, Arheart KL, Lopez-Mitnik G, Lipshultz SE, Livingstone A. Bariatric surgery significantly decreases the prevalence of type 2 diabetes mellitus and pre-diabetes among morbidly obese multiethnic adults: long-term results. J Am Coll Surg. 2011; 212(4): 505-511.
Gagnon C, Brown C, Couture C, Kamga-Ngande CN, Hivert MF, Baillargeon JP, Carpentier AC, Langlois MF. A cost-effective moderate-intensity interdisciplinary weight-management programme for individuals with prediabetes. Diabetes Metab. 2011; 37(5): 410-418.
Katula JA, Vitolins MZ, Rosenberger EL, Blackwell CS, Morgan TM, Lawlor MS, Goff DC Jr. One-year results of a community-based translation of the Diabetes Prevention Program: Healthy-Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care. 2011; 34(7): 1,451-1,457.
Lu YH, Lu JM, Wang SY, Li CL, Zheng RP, Tian H, Wang XL. Outcome of intensive integrated intervention in participants with impaired glucose regulation in China. Adv Ther. 2011; 28(6): 511-519.
Parikh P, Simon EP, Fei K, Looker H, Goytia C, Horowitz CR. Results of a pilot diabetes prevention program intervention in East Harlem, New York City: Project HEED. Am J Public Health. 2010; 100 Suppl 1: S232-S239.
Sakane N, Sato J, Tsushita K, Tsujii S, Kotani K, Tsuzaki K, Tominaga M, Kawazu S, Sato Y, Usui T, Kamae I, Yoshida T, Kiyohara Y, Sato S, Kuzuya H, Japan Diabetes Prevention Program (JDPP) Research Group. Prevention of type 2 diabetes in a primary healthcare setting: Three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health. 2011; 11(1): 40.
Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roque i Figuls M, Richter B, Mauricio D. Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008 Jul; (3): CD003054.
-
References